Cellpoint (Galapagos) and Takeda Present Novel CAR-Ts for Hematological Tumors; EBMT - EHA CAR-T Meeting 2023 Analysis 1
Here is a brief preview of this blast: EBMT – EHA CAR-T Meeting 2023 Analysis 1: Cellpoint (Galapagos) and Takeda presented initial clinical and preclinical data from their CAR-T therapies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: